<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Iraneus Ogu on Medium]]></title>
        <description><![CDATA[Stories by Iraneus Ogu on Medium]]></description>
        <link>https://medium.com/@iraneuso?source=rss-2d9a2452bc3b------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/1*V1VXWnhDrXdwpERyHXvlXg.jpeg</url>
            <title>Stories by Iraneus Ogu on Medium</title>
            <link>https://medium.com/@iraneuso?source=rss-2d9a2452bc3b------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Tue, 17 Nov 2026 19:36:36 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@iraneuso/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Solving a Med Need Live Webinar Series]]></title>
            <link>https://medium.com/medneed/solving-a-med-need-live-webinar-series-28af8a602ca6?source=rss-2d9a2452bc3b------2</link>
            <guid isPermaLink="false">https://medium.com/p/28af8a602ca6</guid>
            <dc:creator><![CDATA[Iraneus Ogu]]></dc:creator>
            <pubDate>Thu, 07 Dec 2023 13:06:55 GMT</pubDate>
            <atom:updated>2023-12-07T13:06:55.966Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*82AtWtpqr-bpLmARAmnCFA.png" /></figure><p>OBJECTIVE</p><p>To provide clinician and life scientists with information and resources for AI applications in healthcare</p><p>FORMAT</p><p>This is an online event.</p><p>DATE</p><p>This Friday</p><p>TIME</p><p>2:00 pm (UTC)</p><p>Please note the equivalent time in your time zone.</p><p>HIGHLIGHTS</p><p>Presentations</p><p>Informative sessions covering key strategic concepts, current landscape, successful case studies, emerging trends, helpful tips, valuable insights and actionable information from subject matter experts and key opinion leaders.</p><p>Financial Clinic</p><p>Access to financial experts and advisors, investor forums, funding sources, payment options, financing consultations, financial strategies, business model feasibility analyses, dedicated financial advice and guidance on projects financing.</p><p>Demo/Pitch</p><p>Live product demonstrations and pitches, recent discoveries and innovative solutions, opportunity to support and scale projects, unique feature and value propositions, explore potential investments and impactful ideas, witness practical applications.</p><p>Questions/Discussions</p><p>Get answers to new and submitted questions on interactive sessions, learn best practices, network and find partners and collaborators, panel discussions, debates on relevant topics, open forum for ideas and knowledge-sharing and participant engagement.</p><p>ATTENDING</p><p>Clinicians, life scientists, healthcare professionals and administrators, key stakeholders</p><p>Health systems, government agencies, non-governmental organizations and associations</p><p>Investors, financiers, financial institutions, family offices, funding agencies and donors</p><p>Developers, manufacturers, innovators of latest products, researchers sharing discoveries</p><p>Send any questions or recommendations to <a href="/service/mailto:admin@medneed.com">admin@medneed.com</a></p><p>STREAMING ON</p><p>LinkedIn: <a href="https://www.linkedin.com/company/medneedservice">https://www.linkedin.com/company/medneedservice</a></p><p>YouTube: <a href="https://www.youtube.com/channel/UC0T29j9UH0W_PO08lljGxQA">https://www.youtube.com/channel/UC0T29j9UH0W_PO08lljGxQA</a></p><p>Facebook: <a href="https://www.facebook.com/medneedservice/">https://www.facebook.com/medneedservice/</a></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*6_5OOoE7ky_To2XkJW1caw.png" /></figure><p>RESOURCES</p><p>The recorded sessions will be available and shared with participants afterwards. Participants will be able to get any clarifications and support beyond the event.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=28af8a602ca6" width="1" height="1" alt=""><hr><p><a href="https://medium.com/medneed/solving-a-med-need-live-webinar-series-28af8a602ca6">Solving a Med Need Live Webinar Series</a> was originally published in <a href="https://medium.com/medneed">Medneed</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Production Mindset vs. Consumption Mindset in the Public and Private Sectors]]></title>
            <link>https://medium.com/@iraneuso/production-mindset-vs-consumption-mindset-in-the-public-and-private-sectors-9ab7540b69bc?source=rss-2d9a2452bc3b------2</link>
            <guid isPermaLink="false">https://medium.com/p/9ab7540b69bc</guid>
            <category><![CDATA[production]]></category>
            <category><![CDATA[society]]></category>
            <category><![CDATA[consumption]]></category>
            <category><![CDATA[business]]></category>
            <category><![CDATA[government]]></category>
            <dc:creator><![CDATA[Iraneus Ogu]]></dc:creator>
            <pubDate>Thu, 23 Feb 2023 11:05:53 GMT</pubDate>
            <atom:updated>2023-02-23T11:53:14.145Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="Some members of the public and private sectors" src="https://cdn-images-1.medium.com/max/672/1*7vzucYFNY_vpjD8IIfTavw.jpeg" /></figure><p>We pray for a time when more people will HONESTLY work for in public sector the way it is mostly done in the private sector, and do for the public good what we desire in our private life.</p><p>We employ the most qualified hands in the private sector, but in the public sector, mostly anything goes. Why?</p><p>In the private sector, we employ and vote for the most trustworthy and competent hands, but we like to do the opposite in the public sector, mainly because of our selfish and dumb interests.</p><p>When we get sick, we look for the most competent hands to treat us without minding where they come from or their belief system. But for public offices, we disregard competence and lower ourselves mainly to tribalism and religious sentiments, yet expect the public service to serve us well.</p><p>We want honest and reliable people to work for us and with us in the private sector, but in the public sector, we do the opposite; and do not mind supporting people with clearly questionable characters or who are likely not to perform well. Why? Is it not mainly to serve our selfish and dumb interests?</p><p>As a result, we find many incompetent people who occupy various positions in governance and civil service leading to bad policies and poor performance in healthcare, education, economy, infrastructure, safety, transportation, energy, etc; in the federal, state, and local levels.</p><p>We forget that the corruption and inefficiency we encourage and practice in one sector might somehow affect us directly or indirectly in another sector, and that what goes around comes around. Think about it for a minute.</p><p>We seem not to realize that when the public sector is dysfunctional, everyone is naturally affected as a member of society, whether we work in the public or private sector.</p><p>Meanwhile, because our governance and civil service are pervaded by nepotism, corruption, inefficiency, and mediocrity, many honest and capable hands either do not want to go into public service, or do not have the opportunity to serve the public good.</p><p>A big issue here is this pervasive “consumption mindset,” especially in this part of the world. People want to consume but think less of how to produce and contribute as human beings. This has led to so much corruption and inefficiency and people wanting to get paid for nothing, whether they work or not.</p><p>A person with a mostly “production mindset” will most likely NOT encourage mediocrity, corruption, and inefficiency since they hunger for better results and desire improved outcomes from available resources. They want to solve problems and make things better to make life meaningful.</p><p>If you bring an idea or project to a person with more of a production mindset, they will likely be more interested in knowing how valuable the idea is; how it will solve problems or make things better. But a person with a more consumption mindset will more likely be looking at what they will selfishly gain or “what is in it for them” and are more likely to garbage good ideas or “sit on your file.”</p><p>If you are hiring, whether in the governance and civil service or private business, please look for people with more of a production mindset. They are more likely to perform, think more of how to contribute to organizational growth, and be objective in matters of organizational performance. On the contrary, people with more of a consumption mindset are more likely to be just interested in how much they get paid and promote selfish interests, which may not benefit the organization.</p><p>The fact is that a person with a productive mindset will more likely do the right thing and work with the right people and policies, whether in the private or the public sector.</p><p>Of course, this is not in any way to suggest that a productive person cannot have character flaws that may make them a terrible person to live or work with; not all at all. A productive person may have all the deficiencies we could attribute to a more consumption-oriented person and even worse. So there could be exceptions.</p><p>However, the point is that a more production-minded person is way more likely to make more effort to build and contribute, focus on important things, be less distracted by frivolities, and tend toward doing the right things. There is a reason they talk about “the idle mind being the devil’s workshop.” Also, there is a reason they talk about “thinking of what you can do for the country and not what the country will do for you.” All are pointing towards the need to be more productivity-oriented.</p><p>In a nutshell, we need to think more of production and less of consumption, no matter where we are, especially in governance and civil service.</p><p>We must promote more honesty, capacity, competence, and the courage to work more for the good of all wherever we find ourselves. This is even the true spirit of religion and humanity, no matter our affiliations, beliefs, or backgrounds. When you say you are made in the image and likeness of God, also know that God is a creative and working God. And to be like God means to work and be creative, which means being productive.</p><p>The time is now for us to do more. We must encourage one another in the public and private sectors to work more towards building better systems and contributing in little and big ways to make things better for all. This gives us dignity today and tomorrow.</p><p>A production mindset encourages innovation, invention, growth, hard work, honesty, service, competence, capacity, and productivity, which make our lives meaningful wherever we are for a better society. This should start in our families and schools and at play and workplaces.</p><p>No matter how we have been thinking and acting, we can decide today to improve our attitude and the way of think and work for better results.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=9ab7540b69bc" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Cost of Care Summit Series]]></title>
            <link>https://medium.com/medneed/cost-of-care-summit-series-6f042ae189c4?source=rss-2d9a2452bc3b------2</link>
            <guid isPermaLink="false">https://medium.com/p/6f042ae189c4</guid>
            <dc:creator><![CDATA[Iraneus Ogu]]></dc:creator>
            <pubDate>Fri, 18 Dec 2020 08:47:39 GMT</pubDate>
            <atom:updated>2020-12-18T08:47:39.075Z</atom:updated>
            <content:encoded><![CDATA[<p>As part of the activities for the Cost of Care Summit 2020 Series, we are inviting more speakers who have experience in healthcare development, finance, management, policy or investments to share their knowledge and insights on <strong>strategies that could help lower cost while improving quality of medical care for more people.</strong></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/603/1*c8a-djEAQehU-WKKHQzc1Q.jpeg" /></figure><p>Please if you are interested, you could <strong>record a 10 to 45 minutes video of your presentation</strong> and we will share with our audience across our media channels. The format is simple; introduce yourself with a brief bio and then proceed with your presentation. We are really happy to get your video this week or next but will continue accepting and sharing entries over the coming weeks.</p><p>And if you know anyone with relevant experience who might be willing to share their perspectives, please kindly refer this person to us.</p><p>If you need more information or have any recommendations please reach out to us at summit@medneed.com or +2347054377387.</p><p>We look forward to your contribution as we work to together to help more people have access to more affordable and timely medical care.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/800/1*Ttg6rTAxvq0kLRJ9sj07Mg.jpeg" /></figure><p>#healthcare #financing #development #costofcare</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=6f042ae189c4" width="1" height="1" alt=""><hr><p><a href="https://medium.com/medneed/cost-of-care-summit-series-6f042ae189c4">Cost of Care Summit Series</a> was originally published in <a href="https://medium.com/medneed">Medneed</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Another Important Life Event]]></title>
            <link>https://medium.com/@iraneuso/another-important-life-event-652540161dcd?source=rss-2d9a2452bc3b------2</link>
            <guid isPermaLink="false">https://medium.com/p/652540161dcd</guid>
            <dc:creator><![CDATA[Iraneus Ogu]]></dc:creator>
            <pubDate>Sun, 30 Aug 2020 15:47:27 GMT</pubDate>
            <atom:updated>2020-08-30T20:48:35.916Z</atom:updated>
            <content:encoded><![CDATA[<p>It might seem crazy, but for long, I struggle with finding meaning in life. Like what’s the purpose of all these noise and drama called “life” with all the anxieties and worries and this and that?</p><p>But at least for now, I think an essential meaning of life (including helping one another) is to join forces with Mother Nature to keep improving this “process of existence” called life.</p><p>So far, two of the most important things I think we should be doing among other things include;</p><p>“a” — Extending and improving the quality of human life as we know it. That is progress in aging and longevity efforts and healthcare as a whole.</p><p>“b” — Finding ways to be a space fairing civilization. Being among the stars and exploring the limits of the universe.</p><p>These two areas of endeavor excite me more than anything else. While they might seem like totally different fields, they are rather closely related. For instance, “a” should be an integral part of “b,” while “b” may tell us a lot about how to do “a.”</p><figure><img alt="ARDD 2020" src="https://cdn-images-1.medium.com/max/295/1*sPxTMrbwf09yS7_rUIC6Mg.png" /></figure><p>In brief, both fields are important in their own right, but I think progress in “a” will make achieving “b” more sustainable in many ways. This comparison is not the aim of this writing, though. The thing is everything I do, for the most part, is to directly or indirectly contribute towards these two goals.</p><p>Now, among the ways I try to keep tabs on some of the developments in the world of aging research and longevity efforts and the related drug discovery is through the prestigious annual <strong>Aging Research and Drug Discovery (ARDD)</strong> meeting. And it’s arrived, holding this <strong>September 1–4</strong>.</p><p>This all-important event is holding virtual this year, and as you might guess, attendance is free.</p><figure><img alt="Aging Research and Drug Discovery Meeting" src="https://cdn-images-1.medium.com/max/677/1*xTXG7nY-vmBP_x1azmJPpw.png" /></figure><p>So I encourage you to register and be part of this gathering to learn from some of the finest people doing amazing things in this space.</p><p>Please you can follow the link <a href="http://agingpharma.org/">http://agingpharma.org</a> to register in just a few minutes.</p><p>Let’s be part of some of the most meaningful efforts ever.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=652540161dcd" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[How Longenesis helps achieve more affordable and improved healthcare delivery]]></title>
            <link>https://medium.com/medneed/how-longenesis-helps-achieve-more-affordable-and-improved-healthcare-delivery-8b8856da2129?source=rss-2d9a2452bc3b------2</link>
            <guid isPermaLink="false">https://medium.com/p/8b8856da2129</guid>
            <category><![CDATA[healthcare]]></category>
            <category><![CDATA[ai]]></category>
            <category><![CDATA[affordable-healthcare]]></category>
            <category><![CDATA[blockchain]]></category>
            <category><![CDATA[healthcare-innovations]]></category>
            <dc:creator><![CDATA[Iraneus Ogu]]></dc:creator>
            <pubDate>Tue, 17 Mar 2020 07:15:28 GMT</pubDate>
            <atom:updated>2020-03-17T09:48:42.812Z</atom:updated>
            <content:encoded><![CDATA[<p>Longenesis is a partnership between Insilico Medicine, a leading artificial intelligence company that uses deep learning for drug discovery, and the Bitfury Group, the leading full-service blockchain technology company. Longenesis is the exclusive healthcare application provider for open-source framework Exonum™.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/415/1*bxj83U2i-hRnBd8sHWShCQ.png" /></figure><p>Longenesis has developed a blockchain solution that uses AI-integrated toolsets to store, manage, analyze, and exchange healthcare-related data such as lab test results. The main goal of the company is to accelerate the development of healthcare by providing the solutions (for pharma, clinics, researchers, data analytics companies, and patients) for data management and data analytics utilizing blockchain and AI technologies.</p><p>The Longenesis health data management solution enables hospitals to upload, store, and manage the data of individual patients in a secure environment, giving full control of data usage and access back to patients. Hospitals can also better handle consent forms and status for individual researchers, which better facilitate the advancement of clinical trials.</p><p>Longenesis is a powerful solution for medical providers, supplying everything from user interfaces for patient interaction to medical recordkeeping. But its main focus has become medical-consent technologies. It streamlines data collection and aggregation, improves medical research processes, and enables transparent patient consent management. This is important as medical data access and security are more carefully regulated worldwide, necessitating technological advances. Thus Longenesis works in compliance with the Health Insurance Portability and Accountability Act (HIPAA) and General Data Protection Regulation (GDPR). Hence, it meets both US and EU standards.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/628/1*s8qbiV5wCrjds9ZmFA2iTw.png" /></figure><p>With its platform, researchers get a fuller picture of patients, and every step of the process is linked, verifiable and auditable. The patient agrees to specified care or participation in a study or a trial. Patients can withdraw that agreement, while the medical provider can offer to extend, modify, or amend the agreement.</p><p><a href="https://medium.com/meetbitfury/bitfury-and-longenesis-launch-medical-consent-solution-457bdf51fc9">Longenesis Themis</a> is a dynamic consent management toolkit solving the legal challenge of legitimate biomedical data utilization for clinical studies, allowing patients to be proactively involved in the clinical and research projects and providing transparency and auditability mechanisms, putting patients as a centric stakeholder of such process.</p><p><a href="https://medium.com/@longenesis/longenesis-enters-the-singapore-market-as-a-participant-of-500-startups-singapore-program-to-ff94f2575fe5">Longenesis Proteus</a> allows any clinical and research institution, patients association, biobank, and MedTech company to join the network and get connected with Clinical Research organizations and Pharma companies for proactive patient involvement.</p><p><a href="https://labsoflatvia.com/en/news/longenesis-joins-forces-with-northern-european-oncologists">Longenesis</a> has also conducted studies on Breast Cancer multi-modal risk calculation, Diabetes patients’ medical treatment monitoring and pharmacovigilance, being well-equipped to address patient needs in the APAC region.</p><p><strong>More Affordable and Improved Healthcare</strong></p><p>Longenesis will be providing its medical-consent platform-as-a-service to hospitals and labs. The system works with pharmaceutical companies and research institutions who can peruse the anonymous metadata to see what information might be available. They can then offer the owner of the data, the patient, the opportunity to participate in trials or studies or release their existing information for use in the evaluation of medicines or procedures. Longenesis offers a transparent chain from the patient through to the hospital making more information available to the researchers, who now face problems of quantity and quality of relevant data.</p><p>Making data available for healthcare innovations like drug discovery and development contributes in many ways to making healthcare more affordable and improving the quality of healthcare available. In a special way it helps in the development of more personalized and potent healthcare products and services.</p><p><strong>Longenesis Media contact:<br> </strong><a href="/service/mailto:info@longenesis.com">info@longenesis.com<br> </a>+37126354885</p><p>This story was originally published on <a href="https://www.medneed.com/post/how-longenesis-helps-achieve-more-affordable-and-improved-healthcare-delivery">MedNeed.com</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=8b8856da2129" width="1" height="1" alt=""><hr><p><a href="https://medium.com/medneed/how-longenesis-helps-achieve-more-affordable-and-improved-healthcare-delivery-8b8856da2129">How Longenesis helps achieve more affordable and improved healthcare delivery</a> was originally published in <a href="https://medium.com/medneed">Medneed</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Has a new day come for pharmaceutical R&D in Africa?]]></title>
            <link>https://medium.com/@iraneuso/has-a-new-day-come-for-pharmaceutical-r-d-in-africa-c83b7cd8c214?source=rss-2d9a2452bc3b------2</link>
            <guid isPermaLink="false">https://medium.com/p/c83b7cd8c214</guid>
            <category><![CDATA[pharmaceutical]]></category>
            <category><![CDATA[ai]]></category>
            <category><![CDATA[biotechnology]]></category>
            <category><![CDATA[africa]]></category>
            <category><![CDATA[healthcare]]></category>
            <dc:creator><![CDATA[Iraneus Ogu]]></dc:creator>
            <pubDate>Thu, 26 Sep 2019 16:30:46 GMT</pubDate>
            <atom:updated>2019-10-03T14:21:06.883Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/732/1*PcXpz-rWo1pIFGuEaDC-TQ.png" /></figure><p>Biology is fundamentally hard. It is way harder than say computer science where we are working with tools we basically made ourselves, and could easily manipulate to the second. On the other hand, we did not originally make our biology. This means that when we work in life science, we are tooling around this complex structure, we did not just make, nor have a full understanding of how it works.</p><p>But then, the more we get to understand something, the better we could manipulate it, and our biology is no different. The more we could fundamentally learn and refine our knowledge of how our biology works at the most basic level, the more we could better control it. And we are doing this already, which is precisely what makes the work at organizations like <a href="http://www.insilico.com/">Insilico Medicine</a> exceptionally powerful. By taking advantage of principles available in both the biological and physical sciences, including computer science, the team at Insilico is trying to understand biological processes and biomarkers at a much deeper level. And then utilizing the processing power and speed of modern computer science, the team is now trying to find ways to solve hard medical problems and make many life science efforts, including pharmaceutical research better overall.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/628/1*STlmGf-M0kAxlbjkmQbUUA.png" /></figure><p>Starting about five years ago, Alex Zhavoronkov and the growing team at Insilico have continually pushed the limits of what could be done in the biological sciences, with the aid of advances in artificial intelligence (AI), and other core biological science tools. Over the years, the team has made lots of original contributions to pharmaceutical research and development, and on the broader aging research and longevity sciences. Now, Insilico has demonstrated that it is possible to have a more definite approach to modern drug discovery with the publication of the landmark work developing the <a href="https://www.nature.com/articles/s41587-019-0224-x">GENTRL platform</a>. This paper is basically a proof of concept on what could be done with AI in the pharmaceutical industry.</p><p>Leveraging AI techniques like generative adversarial networks and generative reinforcement learning, GENTRL (Generative Tensorial Reinforcement Learning) enabled the development of a drug candidate from ideation through in vitro experimentation to in vivo confirmation in just about 46 days. Unprecedented in the recent history of drug discovery and development, this result means that a lot more pharma products could be developed at a much higher pace and with significantly less cost. Naturally, this also means that some of the harder or neglected health and biological challenges could now be better solved. While this is big news for global pharmaceutical development, it is particularly interesting for many parts of the world with a history of inadequate pharma efforts, including Africa.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/628/1*jfCP80KwHSgNJjdNmaCxPA.png" /></figure><p>Traditionally, drug discovery involves the testing of thousands of small molecules to arrive at just a few lead-like molecules and only about one in ten of these molecules pass clinical trials in human patients. This has proved to be costly and vastly inefficient especially in recent times. Also, more often than not, there was little incentive for many pharma companies to work on some rare healthcare challenges, including some diseases of tropical origin. Not a lot of people in pharma try to work on these medical issues, primarily due to economic considerations. Imagine if only the costs are much lower, perhaps more work would be done to fix some of these healthcare challenges.</p><p>Interestingly, during the early stages of drug discovery, machine learning, a subset of AI, has many critical applications such as preclinical screening of drug compounds and prediction of the likelihood of success of a drug compound. AI helps in drug target identification and validation; target-based, phenotypic, and multi-target drug discoveries; drug repurposing; and biomarker identification.</p><p>So benefiting from the increasing availability of useful health data, machine learning helps to vastly reduce the time and costs of drug discovery, and this naturally translates to reduced cost of the drug for the patient in addition to helping bring vital medicines faster to market. Even a slight improvement in the cost and time it takes to discover new medicines means significant savings and public benefit. Insilico is developing a comprehensive drug discovery pipeline utilizing AI generating novel molecules with the specified properties for a variety of target classes and challenging targets.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/505/1*_DMxqmrJBtrghvcp_YbgEg.png" /></figure><p>Healthcare, especially pharma in Africa, is dearly in need of this transformation. In Africa, on average, about 80% of all pharmaceuticals used are imported from outside Africa, and this trend is far from sustainable neither near-term or in the long run. Overall, AI would not only help Africans make more original contributions to global pharma but would help Africans tackle more local health challenges while creating more employment opportunities for the many scientists who could be well employed in Africa to work towards better and more affordable healthcare solutions for all. In the light of these recent developments, especially GENTRL, we could rightly say that clearly, a new day may have arrived for pharma development, especially in Africa.</p><p>As GENTRL now validates the idea that AI for drug development can be widely applied to drug development for various disease challenges, it means that we could in a matter of weeks and at a minimal cost achieve what typically takes years. And the fact that the GENTRL technology is open source means that health professionals and scientists in Africa, especially those with pharmaceutical and biological sciences background, can now consider starting their own drug discovery companies to help improve healthcare locally and at the global scene. This provides developing nations in Africa the opportunity to build their own globally significant pharmaceutical industries by leapfrogging years of pharmaceutical R&amp;D, and can potentially compensate for inadequate local talent while substantively transforming the local health systems.</p><p>Moving forward, it may be challenging, but if we passionately desire to make healthcare better for all, and if we keep an open mind to learning and adopting new things, then it is easier for us to individually and collectively make significant progress, and potentially transform our healthcare locally and beyond. We encourage us to join this effort sooner rather than later towards much better fulfillment overall. AI is a powerful tool that could help us make more progress towards better health for people everywhere.</p><p><strong>Reference to the paper:</strong></p><p>Alex Zhavoronkov, et, al, <a href="https://www.nature.com/articles/s41587-019-0224-x">Deep learning enables rapid identification of potent DDR1 kinase inhibitors</a>, Nature Biotechnology, DOI: 10.1038/s41587–019–0224-x</p><p><strong>Link to the paper: </strong><a href="https://www.nature.com/articles/s41587-019-0224-x">https://www.nature.com/articles/s41587-019-0224-x</a></p><h3><strong>About the Author</strong></h3><p><strong>Iraneus Ogu</strong> directs the Africa Artificial Intelligence and Blockchain for Healthcare Initiative at Insilico Medicine, Inc. In addition to tech developments, he works on Longevity and Aging Interventions with his research efforts focusing on neuroregeneration. He equally works with the development team at Longenesis.com and also has a background in Pharmaceutical Sciences at the University of Greenwich, where his research focused on controlled-release dosage forms.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=c83b7cd8c214" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Achieving UHC with Tools (Part II): How can big data and AI help create better health for all?]]></title>
            <link>https://medium.com/medneed/achieving-uhc-with-tools-part-ii-how-can-big-data-and-ai-help-create-better-health-for-all-f22e2c74ea90?source=rss-2d9a2452bc3b------2</link>
            <guid isPermaLink="false">https://medium.com/p/f22e2c74ea90</guid>
            <category><![CDATA[africa]]></category>
            <category><![CDATA[big-data]]></category>
            <category><![CDATA[healthcare]]></category>
            <category><![CDATA[artificial-intelligence]]></category>
            <category><![CDATA[innovation]]></category>
            <dc:creator><![CDATA[Iraneus Ogu]]></dc:creator>
            <pubDate>Sat, 29 Dec 2018 09:33:36 GMT</pubDate>
            <atom:updated>2019-02-05T09:13:20.426Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/836/1*y6kaGTgUv_M-q0uDS4Chuw.png" /></figure><p>Coming from the <a href="https://medium.com/@iraneuso/achieving-uhc-with-tools-part-i-so-much-talk-about-universal-health-coverage-285329f13033">earlier part</a> of this series, we would be exploring, at a fundamental level, some of the tools for accelerating the attainment of UHC and see how we could be thinking about some of these things better. Currently, big data and its companion, Artificial Intelligence (AI) are two examples of the transformative tools we are exploring and would be looking at them here. We would be starting with how we arrived at big data and after that, how AI is helping maximize the inherent benefits. Without waiting any further, let’s take a look right away.</p><p><strong>In the Beginning</strong></p><p>We have a “need”, which is “better health for ourselves and everybody else.” While we naturally need better health for ourselves and those around us, in especially way we are driven (due to our convictions) or are compelled (as a result of our positions) to help make better health available to everybody.</p><p>To help solve this, we are in search of solutions. Among other things, our most immediate answer is to try to provide adequate healthcare products and services for everybody. To be able to serve our purpose, the healthcare products and services should have some fundamental characteristics. We could call these <a href="https://www.who.int/news-room/fact-sheets/detail/universal-health-coverage-(uhc)">some of the basics</a> of Universal Health Coverage (UHC), and they are:</p><p><strong>Good Quality</strong>: They should serve our purpose; achieve required health outcomes without causing more issues.</p><p><strong>Readily Available and Accessible:</strong> They should be easy to reach; obtainable when needed.</p><p><strong>Very Affordable:</strong> They should not only be cost-effective but within the purchasing power of almost everybody (institutions and individuals alike).</p><p>We want or rather “<strong>need</strong>” these fundamental characteristics within a functional healthcare system where every effort is primarily focused on the patient’s outcomes improvement.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/272/1*pQOgzcgqDltPS0F1ImYDkA.png" /></figure><p>As we always desire to make things better and seek better solutions. We realize that humans are fundamentally tool builders. Humans could build tools that could amplify natural capabilities to exponential levels. So we seek tools that could help us do better. Tools are a form of leverage. It turns out tools from advancements in science and technology could be helpful. Now, it is important to note that technologies, no matter the form, are “tools,” tools to help solve problems and make things better.</p><p>Brilliantly, tech tools when applied to healthcare help us solve some of the healthcare needs and make things better. These include all the standard and novel tools for diagnoses, telemedicine, EMRs and computers, electronic reminders and lots more. We find these helpful.</p><p>Now, because the movement and storage of information in some of these healthcare tools are usually in the digital format (i.e. expressed in digits: 1s and 0s or typically represented by values of physical quantity like voltage or magnetic polarization or two levels of electric charge stored in a capacitor as is found in the semiconductor of most modern computer), we refer to this generally as “digital healthcare” and the information as “digital information”.</p><p>We may now ask: Is the future of healthcare digital? Well, maybe yes, maybe no. However, we have digitized a good chunk of how healthcare works and so far, it seems we are having more quality, available, accessible, and affordable care with more digitization. Maybe we go with progress and adopt more of digital healthcare since digitization is helping us solve more of our problems and make things better, right? Well, the future of healthcare could be digital; if and only if digital healthcare continues to serve us better. By the way, some tools could be costly especially at the early stages. However, they usually get better and more affordable with time and continued improvements.</p><p>In any case, it essential we have an open mind towards progress. What if something different and better than what we are trying to do now comes up tomorrow? Would we be open to explore and go with whatever is better overall? We should be. Usually, it starts with overcoming our mental barriers. This suggests that it is also important not to see some of these tools as the final solution always; our use of them is not cast on stone. They could be better in some situations but maybe not in others. As a result, we should be willing and able to fine-tune products and processes to serve our unique needs better.</p><p>Also, it is not always a nice idea to try so hard to copy whatever progress we see elsewhere and try to shoehorn them into our places including where or when they may not be suitable. The recommendation here is that we should be able to properly adopt and adapt progress and then also learn to make them better. We should work to be able to take whatever we have or are given and make them better. Open mindset and creativity are essential in life and especially in dealing with progress in science and tech. We need more of these in places like Africa. We would talk more on some of these later.</p><p><strong>Getting Big on Data</strong></p><p>As we move and store information in digital format, giving us digital healthcare, we acknowledge that information could also be referred to as data. So technically, another word for information is data. So the books we read, our research processes and findings, our characteristics, our communication, including the things we are reading or saying now; are all data or information. This includes our health information records, our body makeup, our genetic information, the lab tests we did, the diagnostic images, our social pictures and so on.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/251/1*egvp__sjtxf7p8xisXEoaQ.png" /></figure><p>In healthcare, all the information we have given, generated, moved or stored from time immemorial are all information or “data.” So since we are recently adopting more of digital healthcare, all those info that we have given, generated, moved or stored are fundamentally digital information or data. Usually, these are called just “data.”</p><p>As we keep accumulating things (anything at all), they gradually become big, right? Same way, as we kept generating and storing digital data, gradually the data becomes “big.” So we call them “big-data” in comparison to when we had just not so much data stored. The storage is on whatever that could hold digital data, e.g., disk drives, solid state drive, optical disks and so on. As we also know, these storage devices are usually embedded into machines (e.g., computers) that help to process and store these data and bring them up when needed. Also, all of them are tools. In a nutshell, all these tools have improved our healthcare, and as they improve our healthcare, we have also generated and stored lots of data, and these data have become big, and we now call them “big-data.”</p><p>To be clear, the term “big data” refers to massive data sets that may be analyzed computationally to reveal patterns, trends, and associations, primarily relating to human behavior and interactions. It usually has the 3Vs = high volume, wide variety (structured, semi-structured and unstructured) and high velocity for processing. Is there strictly any amount of data to be called big-data? Not quite. However, usually, it is in terabytes, petabytes and even exabytes of data collected over time. We are generating more data today than ever before. For instance, every second, humanity produces 6000 tweets, 40,000 Google searches, and 2 million emails. Moreover, this keeps increasing; by 2019, global web traffic will surpass two zettabytes per year. That’s huge!</p><p>Now, for our big-data in healthcare, we are like; what do we do with them rather than let them stay there “idle,” occupying space and taking costs? Could they help us more? Could we apply them to something? Could they help our decisions, our actions or something? Meanwhile, in almost every other thing we do we refer to data (information) we have acquired and stored somehow, maybe in our brains, in books, reports or whatever. So we are used to using data for our decisions and actions. That’s not new. That’s more like life. However, for big-data, it is now too big, and we don’t bother having them all in our heads to use the analytical skills of our brains on them.</p><p>Well, the standard machines we have; calculators, computer programs and so on are already helping us somehow; at least they help us do quite a lot. However, we need something that could do more if possible. The question then is: Are there possibly other analytical tools that could do more and help us better? Maybe something that could be more “intelligent” (just as we are intelligent) in order to analyze better and derive more insights from big-data better? Good question!</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/284/1*UwqCdbZ6cuUPnc4fE13_0Q.png" /></figure><p>If we could develop something that could help us in these “intelligent” ways, we could decide to call these “artificially” intelligent machines. So we could distinguish them from our “natural or original” intelligence! So whatever that could operate or do things humans strongly associate with intelligence; maybe machines, programs or whatever, we could call them “Artificial Intelligence.”</p><p>So we now go back to our original challenge: How do we make better healthcare available for everybody, especially where it really matters like Africa? Well, this could be a matter of urgency since Africa, according to some reports, have some of the highest global disease burdens and yet the lowest access to adequate healthcare. This stat is not sustainable and should not be acceptable at all!</p><p>So we are like; could the big-data (we already have) when married to this artificial intelligence (which is basically a machine) help our decisions and actions towards better healthcare for all? This could be a computer that can perform operations analogous to learning and decision making in humans. Put differently, this artificially intelligent “machine” would “learn” from available data and then generate insights from the data. (This is also why we would use the term “machine learning” when referring to some artificial intelligence techniques).</p><p>With likely better understanding of what our big-data is (all the information or records in healthcare especially those in digital format), we would be looking better at AI next. See you in part Trois.</p><p><strong>About the Author</strong></p><p><strong>Iraneus Ogu</strong> directs the Africa Artificial Intelligence and Blockchain for Healthcare Initiative at Insilico Medicine, Inc. In addition to tech developments, he works on Longevity and Aging Interventions with his research efforts focusing on neuroregeneration. He equally works with the development team at Longenesis.com and also has a background in Pharmaceutical Sciences at the University of Greenwich, where his research focused on controlled-release dosage forms.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=f22e2c74ea90" width="1" height="1" alt=""><hr><p><a href="https://medium.com/medneed/achieving-uhc-with-tools-part-ii-how-can-big-data-and-ai-help-create-better-health-for-all-f22e2c74ea90">Achieving UHC with Tools (Part II): How can big data and AI help create better health for all?</a> was originally published in <a href="https://medium.com/medneed">Medneed</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[AI and New Africa (Part IV): Applying AI in Africa]]></title>
            <link>https://medium.com/@iraneuso/ai-and-new-africa-part-iv-applying-ai-in-africa-a639e8f10e73?source=rss-2d9a2452bc3b------2</link>
            <guid isPermaLink="false">https://medium.com/p/a639e8f10e73</guid>
            <category><![CDATA[artificial-intelligence]]></category>
            <category><![CDATA[pharmaceutical]]></category>
            <category><![CDATA[africa]]></category>
            <category><![CDATA[research]]></category>
            <category><![CDATA[healthcare]]></category>
            <dc:creator><![CDATA[Iraneus Ogu]]></dc:creator>
            <pubDate>Sat, 29 Dec 2018 08:58:58 GMT</pubDate>
            <atom:updated>2018-12-29T08:58:58.241Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/735/1*rbYgV2z1xEz2N3cLO1_Dzw.png" /></figure><p>Last week, <a href="https://medium.com/@iraneuso/ai-and-new-africa-part-iii-where-are-the-opportunities-in-africa-to-transform-africa-d2840200c96c">we proposed</a> to discuss some concrete applications of AI with a focus on healthcare. Briefly, true AI is when a system can understand and learn from elaborate sets of data while making valid recommendations and suggestions. Worthy of note here is the word “data” which is information or, to be specific, digitally available information. AI relies a lot on the availability of data to train the machine much like humans learn by taking in and analyzing data. The difference here, at a fundamental level, is the idea of machines learning with vast amounts of data over a much shorter period at an accelerated speed. So it is about trying to accelerate and optimize the rate at which machines take in data, analyze the data and learn from the data in order to make more accurate and valid recommendations and suggestions where needed.</p><p>We are at the dawn of a technological revolution of greater magnitude than the internet and mobile communication technologies. In recent times, hardly a day goes by without the announcement of an incredible new frontier in AI. However, most of the current hype around AI is due to a technique called deep learning (DL). AI, especially DL, has found use in many industries and facets of life from communication to transportation, from customer service to finance and from manufacturing to healthcare and beyond. Overall AI could have potentially disruptive applications, and implications for the current architectural order of the global economy and places like Africa should prepare to take advantage of this as well as necessary inputs.</p><p><strong>AI in Healthcare</strong></p><p>As we reported in a recent post on how <a href="https://medium.com/@iraneuso/with-ai-africa-can-be-the-new-switzerland-the-global-hub-of-pharma-3fb0d14ad0d3">AI could help transform pharma in Africa</a>, AI applications are increasingly being used diagnosis, surgery, patient monitoring and of course drug development and delivery and many healthcare. At the fundamental level, this could be described as <strong>harnessing the power of big data in the life sciences</strong> which involves processing and displaying huge volumes and varieties of health or biological data at a rapid rate.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/269/1*bBjNF6KRzsxSp5CE36dYJg.png" /></figure><p>Currently, this is an increasing trend in many healthcare sectors where there is a vast amount of data such as lab data, insurance data, patient records, research data, and even social media data. In a recent report, CB Insights identified over 100 reputable companies that are applying machine learning algorithms and predictive analytics in various facets of healthcare such as reduce drug discovery times, provide virtual assistance to patients, and diagnose ailments by processing medical images, among other things.</p><p>Many major medical and pharmaceutical companies are already harnessing the power of artificial intelligence with great results. For example, Johnson and Johnson’s Sedasys system has received FDA approval to deliver anesthesia for standard procedures like colonoscopies automatically. A doctor oversees multiple machines at once, making the cost much less than a dedicated human anesthesiologist. <a href="http://www.insilico.com/">Insilico Medicine</a> has taught its AI system to predict the therapeutic use of new drugs before they even enter the testing process. There are also numerous robots in various stages of testing and approval for diagnosing disease.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/266/1*gTjqQxzwTSHHc9-LxgynwQ.png" /></figure><p>Healthcare organizations are <a href="http://techgenix.com/ai-and-big-data/">increasingly making an effort to automate</a> the diagnosis process by developing big data platforms to increase the speed of healthcare practice and research. In some cases, <a href="http://www.analyticsearches.com/wps-seven-industries-that-will-be-taken-over-by-ai/">such as with IBM’s Watson</a>, these machines have a higher accuracy rate for diagnoses than human doctors. The application of AI and big-data in some of these healthcare processes enables systems to monitor complex patterns, thereby allowing for increased effectiveness when it comes to identifying diseases and forming proper diagnoses. Even ultrasound, for instance, now uses AI and cloud-based systems as well as 3D imaging technology to achieve better precision and accuracy. According to Harpreet Singh Buttar, an analyst at Frost &amp; Sullivan, “by 2025, AI systems could be involved in everything from population health management to digital avatars capable of answering specific patient queries.”</p><p>Now we are having more of virtual follow-ups. This means the clinical staff, no longer have to devote so much time follow-up processes. This is because patients now have the option of following up via digital methods and tools such as digital apps and other AI procedures. Also there are now smart robot apps that could answer frequently asked questions and track the patient’s health with some apps going further to give recommendations to patients based on their current diagnosis and past medical reports. No wonder an increasing number of patients are encouraged to go digital.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/260/1*Fnq_Q3MDFj_MowvYgANsLA.png" /></figure><p>Moreover, all the other healthcare tech tools (both old and new) which help make healthcare digital; diagnostics, telemedicine, EMR, networked EMR (intranet or internet), equipment connected over computers, drug reminders, drug selfies and so on, could now have AI or intelligent programs built into them. As a result, these tools suddenly become smarter, learn from data and help us work more intelligently.</p><p>At the core, AI facilitates accessibility, relevance, and actionability of healthcare information. A little more in-depth look at a significant application of AI in healthcare, precisely the pharmaceutical industry, would be helpful.</p><p><strong>New Dawn for Africa; transforming into the global pharma hub</strong></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/724/1*dN5QoNujR0A68nq8xsGapg.png" /></figure><p>We have discussed some of these extensively in <a href="https://medium.com/@iraneuso/with-ai-africa-can-be-the-new-switzerland-the-global-hub-of-pharma-3fb0d14ad0d3">a recent post</a>. While discussing the future of pharma, Dr. Bertalan Mesko says that “medical decision making with artificial intelligence using the power of supercomputers will change everyday medicine. Cognitive computers, such as IBM Watson, have been used in many ways <a href="https://medicalfuturist.com/6-surprising-trends-shaping-the-future-of-pharma/">to analyze big data</a>, not only in genomic research but also in biotechnology. This will also shape the way new drugs are found. It might lead to the end of human experimentation through detailed simulation of human physiology. Our era, with drugs being tested on actual people, will seem barbaric to people of the future. What if supercomputers could test thousands of drug targets on billions of simulations modeling the physiology of the human body in seconds? Pharma should support such research for their benefit.”</p><p>As we already know and it’s good to remind ourselves at this point that AI and most other tech advances are fundamentally just “tools,” <strong>tools to solve problems and make things better</strong>. So the question is: Are there problems in pharma that need to be addressed? Are there pharma processes that need to be improved, enhanced and made better? Well anybody close to pharma knows there are long-standing problems seeking solutions and processes deserving improvements right from actual drug discovery and developments to actual delivery.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/271/1*XKsI2VaHfszPNrdUFdoYQQ.png" /></figure><p>A typical application of AI is in drug discovery. In nature and within pharmaceutical companies are vast amounts of molecules and compounds that could be suitable solutions to combat specific diseases and improve health, but the challenge lies in identifying them as such; as potential therapeutic entities. Drug discovery and development is likely not only the most prominent challenge but also the most significant opportunity for improvement in healthcare. Finding a new drug could be very demanding and cost prohibitive. It takes much time with substantial financial and intellectual demands. At the basic level, these are usually due to the necessary processes needed to ensure we have drugs that are effective and safe for use. On average, the processes involved in making drugs available, from discovery to administration, could cost pharmaceutical companies up to $2.6 billion and could take about 12 to 14 years to complete. Due to this, the leading short to long-term applications of AI in pharma is more towards reducing the time and hence the cost of drug development. This would not only enhance the return on investment and reduce the costs for users but would be helpful in making useful products available faster, especially where it matters most.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/293/1*4isSbTi548EqL1rtL9x_-Q.png" /></figure><p>Usually, thousands of molecules are typically studied and passed through lots of processes and from which only a handful could get to clinical trials, with maybe two to none getting approved as drug out of about ten thousand molecules studied on average. The questions then are: Is there a way AI could quickly help pharmaceutical developers avoid spending too many resources on doomed to fail molecules? Could pharmaceutical developers focus more on just a handful of the most potent molecules that could end up being suitable and approved for their specific purposes? The result would be drastically cutting down on the resources spent, accelerating the drug discovery process and ensuring that better quality drugs are discovered. Well, it turns out AI could be helpful and AI, as we acknowledge, is currently finding applications in almost every aspect of the drug discovery process.</p><p>A handful of AI focused companies including, Insilico Medicine, Atomwise, Numerate and others are doing much work and processing large clinical and medical data to help the pharma do better. Many, including <a href="https://www.prnewswire.com/news-releases/insilico-medicine-earns-accolades-from-frost--sullivan-for-its-pioneering-rd-in-ai-for-aging-research-and-drug-discovery-300667607.html">Frost &amp; Sullivan</a>, have recently recognized the effort at <a href="https://www.prnewswire.com/news-releases/insilico-medicine-earns-accolades-from-frost--sullivan-for-its-pioneering-rd-in-ai-for-aging-research-and-drug-discovery-300667607.html">Insilico</a> Medicine. Even with the current rate of progress (and the pace is accelerating), there would likely be a reduction in the cost of medical treatments by half across the board within the next couple of years.</p><p>There has been this recurring theme among some people in Africa, in both high and low places. They are of the opinion that it would be near impossible to do serious research, develop drugs and make more original contributions to pharma at a global level from Africa. Many of these people usually cite the prohibitive and increasing costs of drug research and development as something many African organizations interested in pharma cannot afford. For them, African institutions are bound to rudimentary research efforts that are mostly bound for the shelves. Many acknowledge this as utterly unsustainable. Thankfully with the aid of advances in tech especially AI there is now absolutely no reason why scientists and developers in Africa cannot be more productive and innovative towards achieving better drug discovery outcomes. This would likely transform pharma and healthcare overall.</p><p><strong>About the Author</strong></p><p><strong>Iraneus Ogu</strong> directs the Africa Artificial Intelligence and Blockchain for Healthcare Initiative at Insilico Medicine, Inc. In addition to tech developments, he works on Longevity and Aging Interventions with his research efforts focusing on neuroregeneration. He equally works with the development team at Longenesis.com and also has a background in Pharmaceutical Sciences at the University of Greenwich, where his research focused on controlled-release dosage forms.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=a639e8f10e73" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[AI and New Africa (Part III): Where are the opportunities in Africa to transform Africa?]]></title>
            <link>https://medium.com/@iraneuso/ai-and-new-africa-part-iii-where-are-the-opportunities-in-africa-to-transform-africa-d2840200c96c?source=rss-2d9a2452bc3b------2</link>
            <guid isPermaLink="false">https://medium.com/p/d2840200c96c</guid>
            <category><![CDATA[africa]]></category>
            <category><![CDATA[artificial-intelligence]]></category>
            <category><![CDATA[data]]></category>
            <category><![CDATA[innovation]]></category>
            <category><![CDATA[healthcare]]></category>
            <dc:creator><![CDATA[Iraneus Ogu]]></dc:creator>
            <pubDate>Sat, 22 Dec 2018 13:28:08 GMT</pubDate>
            <atom:updated>2018-12-22T13:28:08.871Z</atom:updated>
            <content:encoded><![CDATA[<p><strong>AI and New Africa (Part III): Where are the opportunities in Africa to transform Africa?</strong></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/731/1*c5bb0aaERVLSmEjnA_menw.png" /></figure><p>We could comfortably go with the cliché, “opportunities are everywhere.” With quite a lot to do to improve the life of people in Africa, the opportunities to transform Africa could, in fact, be virtually everywhere. There is just a lot to improve at almost every turn. Briefly, some of the areas which we could quickly apply AI technologies to help transform include; Healthcare, Agriculture, Manufacturing, Transportation, Energy, Finance, Commerce, Policy, Infrastructure, and Communication. These are more like the basics though, and we could go on and on since there are just plenty of viable improvements to make life better and more meaningful. Some people opine that wherever there is a need to improve efficiency and do things better, AI could most likely be useful. This is huge! However, for brevity, we would not get to details analyzing some of these right away; we do that in subsequent publications.</p><p><strong>Getting Things Done</strong></p><p>At this point, we have acknowledged there is a lot needed to get done in Africa. We equally have seen that AI accompanied with big data could be a transformative tool. If history is any indicator, we as a society, for some reasons, do not understand some of these technological developments for what they are; just tools! That is tools to help us get things done or maybe solve problems. Realizing and appreciating this fact could ease some of the complications that could come up when using or applying some of these tech advancements. When we see them for what they are; just tools, we are then better positioned to work from the concept of “how could we best apply these tools to get things done.” That is to say, for solving problems or making things better.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/319/1*L_8yOVb52GqbL7b7Kvuekg.png" /></figure><p>There are lots of advantages that come with having this mindset and using this approach as opposed to seeing tech developments as something too uncanny which we do not understand. With the right mindset, it is easier for us to look at problems from a holistic point of view so we could pick the right tool(s) to help us solve problems efficiently. This helps us analyze these tools for what they are and see if they are fit for the purposes to which we want them applied. Doing so would ensure we are on the right track of proper tool application or combination that could work for us, as against applying technologies in areas where they would not be suitable. Not getting could mean we find if more challenging using the tools to solve the problem(s), or they won’t be of any help at all. However, with better understanding, it is easier for us to explore and apply tools appropriately when there are options and alternatives.</p><p>We also need to realize that learning and applying these tools could be challenging especially for new users and those who do not have the relevant background. Well, even those with tech backgrounds may find picking up different or new tech challenging. However, with the right mindset, learning can be more fun and mastering tech applications becomes much easier.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/223/1*8boKNqSxbiCbNys4xZX_nw.png" /></figure><p>What this implies is that as we prime <a href="https://medium.com/@iraneuso/ai-and-new-africa-part-i-data-is-the-new-oil-ai-is-the-new-combustion-engine-could-africa-be-ec9c5817302d">Africa to be the new Silicone Valley (SV)</a> at scale, we need to find a way to accelerate the learning and application of relevant tools for accelerated developments. Becoming the new SV makes more sense only if we could take advantage of transformative technologies like AI, to achieve goals at the fastest rates possible. We, therefore, make a case for organizations and individuals to use more of this “Problems to Tools” approach rather than the “Tools to Problems” approach which society has sort of become accustomed to, especially in our educational and training systems. We are going to delve more in-depth on this in subsequent publications. In a nutshell, let’s acknowledge the importance of analyzing problems we want to solve, seek to understand the underlying grounds and then execute a data-driven solution using the relevant tool.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/251/1*egvp__sjtxf7p8xisXEoaQ.png" /></figure><p>The importance of data for AI developments cannot be overemphasized. As we may now be aware, advancements in AI took off big time in recent years due to the massive volume of accumulated data which were made possible by the use of computers and other digital information and communication technologies. In Africa, much like other parts of the world, massive loads of data are being generated on a daily bases. Advancements in internet made it possible to accumulate data in a way that could easily be synchronized to tech developments like AI for more accelerated and real-time processes. Comparing AI developments and data with the combustion engine and oil respectively, the more data we collect, the better AI will become. However, the question is “how do we ensure we continue to make useful data available in Africa?” This is very important for areas like healthcare in which AI is finding increasing applications. While data could be accumulated easily and at times for free, it could also be hard to gather quality and relevant data for some AI developments when they are needed.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/360/1*WM2WtW5YNHEYkIf18708Fg.png" /></figure><p>To help resolve the challenge of quality and representative data availability, we have come up with <a href="http://www.longenesis.com/">Longenesis</a>, which features a personal data marketplace. This makes it easier for developers to acquire information whenever needed quickly. AI developers will not be the only people to benefit from this but also the patients as well the healthcare professionals. Everybody (you and me) could get some form of payment as an immediate incentive for providing useful data for AI developments. For instance, individuals could be encouraged to go carry out blood tests to generate data that will be used for AI developments, which would then be helpful in making healthcare solutions more personalized and better than ever. It is kind of “data monetization” in the interest of all players. We firmly believe that is some of the proper ways to go about helping improve healthcare in Africa and anywhere else.</p><p>As we <a href="https://medium.com/@iraneuso/ai-and-new-africa-part-ii-what-are-the-challenges-to-meaningful-transformation-in-africa-7a2a9c49d94c#3997-d62d8f18eebb">highlighted earlier</a> in this series, we cannot overemphasize the need for an environment that encourages innovation and the development and deployment of talent. This is very important since most of what we do revolve around people getting things done. A lot has been said about many nations in Africa not providing conducive or suitable environments for innovation and entrepreneurship to thrive. We also talk about the educational systems not equipping students with the adequate skills needed for meaningful work. Moreover, we do talk about people not having access to opportunities that harness their knowledge when they leave the educational and training institutions. Although some of these issues are found almost everywhere in the world, we acknowledge that they are significant issues in Africa. However, most of these challenges have been or are being appropriately addressed in many parts of the world, and for Africa, the development and scaling of innovation hubs could be helpful.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/383/1*ozUDAUMlU-2fGEyN9_fbWA.png" /></figure><p>Innovation hubs could mean many things for many people, but for our purpose, we look at a system that could encourage research and innovation, provide people with skills and training, and provide innovators and producers the resources and opportunities to do better. This system could flow seamlessly online and offline (possibly with units in various locations) and would most certainly be helpful. Scaling this kind of system could be the whole idea of the new SV we are talking about in this series. We know there is a lot more to these, but at least we have a framework for thinking about some of these innovations.</p><p>In any case, transforming Africa into the new SV would entail a lot of liberal thinking and creativity, accelerated productivity and the willingness to explore many options and see what works and what could be optimized and revised. We are optimistic that with the aid of AI we could help accelerate the transformation of Africa into the new SV at an unprecedented scale of progress.</p><p>On the next part of this series, we would look at concrete examples of what we are doing especially in the all-important healthcare. I think this would be very interesting for most people. So see you next week on part quatre.</p><p>About the Author</p><p>Iraneus Ogu directs the Africa Artificial Intelligence and Blockchain for Healthcare Initiative at <a href="http://www.insilico.com/">Insilico Medicine</a>, Inc. In addition to tech developments, he works on Longevity and Aging Interventions with his research efforts focusing on neuroregeneration. He equally works with the development team at Longenesis.com and also has a background in Pharmaceutical Sciences at the University of Greenwich, where his research focused on controlled-release dosage forms.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=d2840200c96c" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Achieving UHC with Tools (Part I): So much talk about Universal Health Coverage]]></title>
            <link>https://medium.com/medneed/achieving-uhc-with-tools-part-i-so-much-talk-about-universal-health-coverage-285329f13033?source=rss-2d9a2452bc3b------2</link>
            <guid isPermaLink="false">https://medium.com/p/285329f13033</guid>
            <category><![CDATA[data]]></category>
            <category><![CDATA[ai]]></category>
            <category><![CDATA[research]]></category>
            <category><![CDATA[africa]]></category>
            <category><![CDATA[healthcare]]></category>
            <dc:creator><![CDATA[Iraneus Ogu]]></dc:creator>
            <pubDate>Thu, 20 Dec 2018 17:44:10 GMT</pubDate>
            <atom:updated>2018-12-20T19:53:44.948Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/707/1*O84PoepYNIGK5-wH-i6IlA.png" /></figure><p>Now, most of us might be aware of Universal Health Coverage (UHC); the idea that everybody should have access to quality and affordable healthcare. Just like many policies that come and go, there is so much big talk around UHC. As I travel more around Africa recently, I come across lots of these talks which are good to hear but then when you think about them better, you realize they have lots of holes. So that you start wondering whether this beautiful goal of UHC is indeed achievable.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/260/1*Nb0hlVUI_FF61XhtnzeGSA.png" /></figure><p>Well, I think, at the core, UHC is quite achievable. However, I believe that attaining UHC starts with more people having this passionate desire to make it work as against just talking about it, perhaps because our jobs demand that we talk about it. It requires more people who really want to do whatever it takes to make it work. This needs more people who see healthcare as a means to help people have and maintain health and not just a business for mere money making. This requires more people who seek a healthier world at the very core.</p><p>To be clear, I do not want to bother us with so much talk about UHC here. Neither do I intend to assert that I would give the panacea for making UHC work. However, what I do want us to try to do here is look at ways we could be prioritizing and thinking more about things that likely have the potentials to be massively helpful as we work towards UHC. And the way we are going to be doing that is to “think more about tools that would help make UHC work for more people.” So we are going to leave most of the talks and focus on tools that could help us get things done better and faster.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/303/1*WzLkgtbIyX1uxD0xI5MLJg.png" /></figure><p>For starters, according to the <a href="https://www.who.int/health_financing/universal_coverage_definition/en/">World Health Organization (WHO)</a>, UHC means that all people and communities can use the promotive, preventive, curative, rehabilitative and palliative health services they need, [and that these should be] of sufficient quality to be effective, while also ensuring that the use of these services does not expose the user to financial hardship. This revolves around having the right people, right products, right policies, adequate funding, adequate infrastructure, and just about every other helpful tool. In summary, we need to have a system where healthcare is available, accessible, affordable and of good quality.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/280/1*7t21KdothZu5Vvv8Vsf9Aw.png" /></figure><p>Now, thinking of tools, we could ask; are their tools within or outside our current healthcare system that could help us achieve these goals, criteria or attributes faster? Moreover, we need to ask this question at every step of the way. Not just at the seemingly more significant decisions but on every step of the way. This means seeking better tools, not only at a high level but in every sub-problem or sub-level. To put things in perspective, let’s look at two areas in which we are actively developing tools that could help accelerate progress and transform everything.</p><p>We start with research. I choose to begin with research because researching and innovating are at the core of most meaningful developments. Sadly, many people usually do not think of how to improve their system and make original contributions to healthcare development; we like to depend on other people for improvements. Well, that’s not how to get better fast. In health research, we focus on how to accelerate the rate of drug discovery, and I think it is an excellent example of how to stimulate the attainment of UHC, on both local and global levels.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/713/1*MGlUnRrvlW8cFDYIhv_AZg.png" /></figure><p>Most times we talk about the need to reduce the cost of drugs. Apparently for UHC to work well, drug and similar products should be very affordable. However, among the most significant contributors to the high cost of drugs is the fact that usually, drug developers spend a lot of resources in time and money doing research. This prohibitive cost not only makes drugs costly but also prevents many intending individuals and organizations (especially in the developing regions of the world like Africa) from getting involved in serious research and development efforts.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/269/1*q8uOG8Min94NkS5Y8-OdSA.png" /></figure><p>Interestingly, this is where tools come in. So we now ask; are there tools that could help us bring down the costs while helping us do better drug R&amp;D work with potentially better outcomes than the traditionally costly methods? So can we improve the processes and make better drugs faster and cheaper? Now, if the process of drug making becomes more economical and quicker, we would likely have more affordable medicines. We could then channel saved resources to even more drug developments so that more useful and quality drugs would be developed and brought to market faster. Imagine for a minute the impact this would have on the effort towards realizing UHC, locally and globally!</p><p>At this very moment, this is what the tool of artificial intelligence (AI) is doing for drug development. For instance, procedures that took upwards of 3–4 years could now be accomplished in a matter of months, saving huge costs while accelerating the rate at which essential drugs are brought to market. It is pleasing that <a href="http://insilico.com/">Insilico Medicine</a> is among the global leaders in this effort. Insilico Medicine’s effort in drug discovery and aging research has been <a href="https://www.prnewswire.com/news-releases/insilico-medicine-earns-accolades-from-frost--sullivan-for-its-pioneering-rd-in-ai-for-aging-research-and-drug-discovery-300667607.html">acclaimed widely</a>.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/262/1*2Ob3n95RSPiM5b6B8K6wGA.png" /></figure><p>Meanwhile, there is a need for researchers to collaborate more. There is a need for more human life data to be channeled to AI developments. There is a need to ensure that representative data from all over the world are made available for AI developments. Among other benefits, this would help train better AI systems and also help avoid bias in AI-enabled developments and other similar health developments. There is a need to ensure that data is well handled with adequate privacy and access controls coupled with efficient movement and storage of data. Moreover, there is a need for healthcare professionals and patients to derive more value from human life data and be rewarded adequately as an incentive to generate more quality data. <a href="http://longenesis.com/">Longenesis</a> is trying to solve these and more.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/283/1*NtQGP0IiKmsODCqRAu6y0A.png" /></figure><p>While I am actively promoting these efforts and tools, it is evident that they are helping “solve real problems and are making things better” towards the realization of UHC for individuals and communities. By the way, I think it is important to start this series with concrete examples of what I know. If we could accelerate the rate of medical discovery while helping healthcare practitioners and researchers do better, then we could rightly be said to be on the fast lane towards UHC. Moreover, if we could somehow also directly incentivize healthcare professionals and patients to take better care of themselves, which is part of what <a href="https://www.eurekalert.org/pub_releases/2017-11/imi-cba111417.php">Longenesis does</a>, then I think that’s really cool outcome!</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/269/1*SScg80nFx8VgWVtcS2so0g.png" /></figure><p>So it is easy to see that seeking and applying tools not only helps enhance the work and skill of professionals but also helps us have better products, helps us reduce costs, and helps us have better analytical tools, which allows better information for better policies. So what is next? Achieving UHC becomes entirely realizable much faster. We could apply this way of thinking to almost every aspect of healthcare and requirements for UHC. It becomes evident that if we could think more concerning tools (practical tools for that matter) which could be helpful in extending our capabilities at every step of the way, we could accelerate the rate of attainment of UHC for people everywhere.</p><p>In subsequent parts of this series, we would be looking at other examples of tools for accelerating the attainment of UHC and how we could be thinking about some of these things better.</p><p>See you next week on part deux.</p><p><strong>About the Author</strong></p><p><strong>Iraneus Ogu</strong> directs the Africa Artificial Intelligence and Blockchain for Healthcare Initiative at Insilico Medicine, Inc. In addition to tech developments, he works on Longevity and Aging Interventions with his research efforts focusing on neuroregeneration. He equally works with the development team at Longenesis.com and also has a background in Pharmaceutical Sciences at the University of Greenwich, where his research focused on controlled-release dosage forms.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=285329f13033" width="1" height="1" alt=""><hr><p><a href="https://medium.com/medneed/achieving-uhc-with-tools-part-i-so-much-talk-about-universal-health-coverage-285329f13033">Achieving UHC with Tools (Part I): So much talk about Universal Health Coverage</a> was originally published in <a href="https://medium.com/medneed">Medneed</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
    </channel>
</rss>